Real-world effectiveness of lanreotide autogel in patients with advanced gastroenteropancreatic neuroendocrine tumours with antigen Ki-67 proliferation index above and below 10%: The KINETICS study

#4579

Introduction: The somatostatin analogue lanreotide is an established treatment option for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with a Ki-67 proliferation index (Ki-67) <10%. There is a paucity of real-world evidence on lanreotide treatment outcomes in patients with well-differentiated (WD) GEP-NETs with a Ki-67 ≥10%.

Aim(s): To investigate the effectiveness of lanreotide autogel (LAN) in the real-world treatment of GEP-NETs in patients with a Ki-67 ≥10% or <10%.

Materials and methods: KINETICS is an ongoing, retrospective, longitudinal real-world cohort study. It includes patients from seven NET centres in Europe with functional or non-functional grade 1, grade 2 or WD grade 3 GEP-NETs that are unresectable, locally advanced or metastatic, who initiated LAN as first-line monotherapy between 1 March 2015 and 31 December 2022. Within each centre, a random sampling approach based on a double stratification (by Ki-67 and primary tumour site) is applied. Patients identified with Ki-67 ≥10% in both sites (gastrointestinal NETs and pancreatic NETs) are 1:1 randomly matched to patients with Ki-67 <10% at the same tumour site to ensure both Ki-67 cohorts have similar distribution of the primary tumour site. The primary endpoint is progression-free survival, both overall and for the Ki-67 cohorts. Secondary endpoints include overall survival and time to next treatment or death.

Conference:

Presenting Author: Vandamme T

Authors: Vandamme T, Gerard L, Del Olmo-Garcia M, de Mestier L, Kiesewetter B,

Keywords: effectiveness, gastroenteropancreatic neuroendocrine tumour, GEP-NET, Ki-67 proliferation index, Ki-67, lanreotide, somatostatin analogue, somatostatin, real-world,